Received Aug 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | X4T99 | SC |
instead of administering intramuscularly give this vaccine subcutaneously; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 17-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number X4T99, expiry date 30-SEP-2025) for prophylaxis. On an unknown date, the patient received Menveo (subcutaneous). On an unknown date, an unknown time after receiving Menveo, the patient experienced intramuscular formulation administered by other route (Verbatim: instead of administering intramuscularly give this vaccine subcutaneously). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 28-JUL-2025 The pharmacist reported that the reporter had an immunization question that was for Menveo. The reporter question was one of staff vaccination, instead of administering intramuscularly give this vaccine subcutaneously to a 17 years old patient which led to intramuscular formulation administered by other route. The reporter asked did they need to readminister.